Центральные и гуморальные механизмы формирования артериальной гипертензии у женщин

1. Быстрова М.М., Бритов А.Н. Артериальная гипертония у женщин в постменопаузе. Кардиология. 1999; 5: 72–80. / Bystrova M.M., Britov A.N. Arterial'naia gipertoniia u zhenshchin v postmenopauze. Kardiologiia. 1999; 5: 72–80. [in Russian]
2. Оганов Р.Г., Масленникова Г.Я. Гендерные различия кардиоваскулярной патологии. Кардиоваск. терапия и профилактика. 2012; 11 (4): 101–4. / Oganov R.G., Maslennikova G.Ia. Gendernye razlichiia kardiovaskuliarnoi patologii. Kardiovask. terapiia i profilaktika. 2012; 11 (4): 101–4. [in Russian]
3. Lloyd-Jones DM, Evans JC, Levy D. Hypertension in adults across the age spectrum: current outcomes and control in the community. JAMA 2005; 294: 466–72.
4. Mosca L, Hammond G, Mochari-Greenberger H et al. Fifteen-Year Trends in Awareness of Heart Disease in Women Results of a 2012 American Heart Association National Survey. Circulation published online February 19, 2013; available at http://circ.ahajournals.org/content/early/2013/02/19/CIR.0b013e318287cf2f
5. Taddei S. Blood pressure through aging and menopause. Climacteric 2009; 12 (Suppl. 1): 36–40.
6. Thom T, Haase N, Rosamond W et al. Heart disease and strokestatistics – 2006 update: a report from the American heart association statistics committee and stroke statistics subcommittee. Circulation 2006; 113: e85–151.
7. Mosca L, Appel LJ, Benjamin EJ et al. Evidence-based guidelines forcardiovascular disease prevention in women. Circulation 2004; 109: 672–93.
8. Беляков Н.А., Сеидова Г.Б., Чубриева Н.В., Глухов Н.В. Метаболический синдром у женщин. СПб.: Издательский дом СПбМАПО, 2005. / Beliakov N.A., Seidova G.B., Chubrieva N.V., Glukhov N.V. Metabolicheskii sindrom u zhenshchin. Spb.: Izdatel'skii dom SPbMAPO, 2005. [in Russian]
9. Bittner V. Women and coronary heart disease risk factors. J Cardiovasc Risk 2002; 9 (6): 315–22.
10. Kannel WB. The Framingham Study: historical insight on the impact of cardiovascular risk factors in men versus women. J Gend Specif Med 2002; 5 (2): 27–7.
11. Gangar KF, Vyas S, Whitehead M et al. Pulsatility index in internal carotid artery in relation to transdermal oestradiol and time since menopause. Lancet 1991; 338: 939–42.
12. Majmudar NG, Robinson SC, Ford GA. Effect of the Menopause, Gender and Hormone Replacement Therapy on Vascular Nitric Oxide Activity. J Clin Endocrinol Metab 2000; 85 (4): 1577–83.
13. Collins P, Rosano GMC, Jiang C et al. Cardiovascular protection by oestrogen – a calcium antagonist effect? Lancet 1993; 341: 1264–5.
14. Lieberman EH, Cerhard MD, Uehata A et al. Estrogens improves endothelium-dependent, flow-mediated vasodilatation in postmenopausal women. Ann Intern Med 1994: 121: 936–42.
15. Wogensen L. Transforming growth factor beta1-induced glomerulopathy is prevented by 17beta-estradiol supplementation. Virchows Arch 2004; 444: 561–6.
16. Birch Nielsen C, Krag S, Osterby R et al. Transforming growth factor beta1-induced glomerulopathy is prevented by 17beta-estradiol supplementation. Virchows Arch 2004; 444: 561–6.
17. Simoncini T, Genazzani AR. Non-genomic actions of sex steroid hormones. Eur J Endocrinol 2003; 148: 281–92.
18. Neugarten J, Acharya A, Lei J, Silbiger S. Selective estrogen receptor modulators suppress mesangial cell collagen synthesis. Am J Physiol Renal Physiol 2000; 279: F309–18.
19. Fisman EZ, Tenenbaum A, Pines A. Systemic hypertension in postmenopausal women: a clinical approach. Curr Hypertens Rep 2002; 4 (6): 464–70.
20. Schunkert H, Danser AH, Hense HW et al. Effects of oestrogen replacement therapy on the renin-angiotensin system in postmenopausal women. Circulation 1997; 95 (1): 39–45.
21. Wood MJ, Cox Jl. HRT to prevent cardiovascular disease. What studies show, how to advise patients. Postgrad med 2000; 108 (3): 59–72.
22. Henriksson P, Stege R, Green K. Profound decrease of in vivo formation of thromboxane during oestrogen therapy. Eur J Clin Invest 1996; 26 (12): 1186–8.
23. Tostes RC, Nigro D, Fortes ZB et al. Effects of estrogen on the vascular system. Braz J Med Biol Res 2003; 36 (9): 1143–58.
24. Kalish MK, Barret-Connor E, Laughlin GA, Gulansky BI. Association of endogenous sex hormones and insulin resistance among postmenopausal women: results from the postmenopausal estrogen/progestin intervention trial. J Clin Endocrinol Metab 2003; 88 (4): 1646–52.
25. Carr MC. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab 2003; 88 (6): 2404–11.
26. Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010; 17 (2): 242–55.
27. Barbagallo M, Shan J, Pang PK, Resnick LM. Vascular effects of progesterone: role of intracellular calcium metabolism. Am J Hypertens 1995; 8 (4): 66A.
28. Landau RL, Poulos JT. The metabolic influence of progestins. Adv Metab Disord 1971; 5: 119–47.
29. Laragh JH. Renin-angiotensin-aldosteron system for blood pressure and elecrolyte homeostasis and its involvement in hypertension, in congestive heart failure and in associated cardiovascular damage (myocardial infarction and stroke). J Hum Hypertens 1995; 9 (6): 385–90.
30. Sealey JE, Itskovitz-Eldor J, Rubattu S et al. Estradiol and progesterone related increases in renin-aldosteron system during ovarian stimulation and early pregnancy. J Clin Endocrinol Metab 1994; 79 (1): 258–64.
31. Staessen JA, Bieniaszewski L, Brosens I, Fagard R. The epidemiology of menopause and associated cardiovascular disease. In: Hypertension after menopause. M.Stimpel, A.Zanchetti (ed.). de Gruyter. Berlin–New-York, 1997; p. 21–9.
32. Ярных Е.В. Артериальная гипертония у женщин в климактерическом периоде: клинические особенности, состояние дофаминергической активности и инсулинорезистентности. Обоснование гипотензивной терапии: Автореф. дис. … канд. мед. наук. М., 2000. / Iarnykh E.V. Arterial'naia gipertoniia u zhenshchin v klimaktericheskom periode: klinicheskie osobennosti, sostoianie dofaminergicheskoi aktivnosti i insulinorezistentnosti. Obosnovanie gipotenzivnoi terapii: Avtoref. dis. … kand. med. nauk. M., 2000. [in Russian]
33. Маличенко С.Б., Овчинникова С.Г. Постменопаузальный метаболический синдром: новые возможности терапии. Фарматека. 2004; 6 (84): 73–8. / Malichenko S.B., Ovchinnikova S.G. Postmenopauzal'nyi metabolicheskii sindrom: novye vozmozhnosti terapii. Farmateka. 2004; 6 (84): 73–8. [in Russian]
34. Jiroutek MR, Chen MH, Johnston CC, Longcope C. Changes in Reproductive Hormones and Sex Hormone-Binding Globulin in a Group of Postmenopausal Women Measured Over 10 Years. Menopause 1998; 5: 90–4.
35. Fortepiani LA, Zhang H, Racusen L et al. Characterization of an animal model of postmenopausal hypertension in SHR. Hypertension 2003; 41: 460–3.
36. Laughlin GA, Barrett-Connor E, Kritz-Silverstein D, Von Muhlen D. Hysterectomy, oophorectomy, and endogenous sex hormone levels in older women: the Rancho Bernardo study. J Clin Endocrinol Metab 2000; 85: 645–51.
37. Hartmann BW, Kirchengast S, Albrecht A et al. Androgen Serum Levels in Women With Premature Ovarian Failure Compared to Fertile and Menopausal Controls. Gynecol Obstet Invest 1997; 44: 127–31.
38. Overlie I, Moen MH, Morkfid L et al. The Endocrine Transition Around Menopause – a Five Years Prospective Study with Profiles of Gonadotropins, Estrogens, Androgens and SHBG Among Healthy Women. Acta Obstet Gynecol Scand 1999; 78: 642–7.
39. Janssen I, Powell LH, Kazlauskaite R, Dugan SA. Testosterone and Visceral Fat in Midlife Women: The Study of Women's Health Across the Nation (SWAN) Fat Patterning Study. Obesity 2010; 18: 604–10.
40. Janssen I, Powell LH, Crawford S et al. Menopause and the Metabolic Syndrome. The Study of Women’s Health Across the Nation. Arch Intern Med 2008; 168 (14): 1568–75.
41. Chen YF, Naftilan AJ, Oparil S. Androgen-Dependent Angiotensinogen and Renin Messenger RNA Expression in Hypertensive Rats. Hypertension 1992; 9: 456–63.
42. Ellison KE, Ingelfinger JR, Pivor M, Dzau VJ. Androgen Regulation of Rat Renal Angiotensinogen Messenger RNA Expression. J Clin Invest 1989; 83: 1941–5.
43. Katz FH, Roper EF. Testosterone effect on renin system in rats. Proc Soc Exp Biol Medical 1977; 155: 330–3.
44. Van Kesteren PJ, Kooistra T, Lansink M et al. The effects of sex steroids on plasma levels of marker proteins of endothelial cell functioning. Thromb Haemost 1998; 79: 1029−33.
45. Stener-Victorin E, Jedel E, Janson PO, Sverrisdottir YB. Low-frequency Electro-Acupuncture and Physical Exercise Decrease High Muscle Sympathetic Nerve Activity in Polycystic Ovary Syndrome. Am J Physiol Regul Integr Comp Physiol 2009; 3.
46. Orentreich N, Brind JL, Vogelman JN et al. Long-term longitudinal measurements of plasma dehydroepiandrosterone sulfate in normal men. J Clin Endocrinol Metab 1992; 75: 1002–4.
47. Sulcova J, Hill M, Hampl R, Starka L. Age and sex related differences in serum levels of unconjugated dehydroepiandrosterone and its sulphate in normal subjects. J Endocrinol 1997; 154: 57–62.
48. Schriock ED, Buffington CK, Hubert GD et al. Divergent correlations of circulating dehydroepiandrosterone sulfate and testosterone with insulin levels and insulin receptor binding. J Clin Endocrinol Metab 1988; 66: 1329–31.
49. Suzuki M, Kanazawa A, Hasegawa M et al. A close association between insulin resistance and dehydroepiandrosterone sulfate in subjects with essential hypertension. Endocr J 1999; 46: 521–8.
50. Celec P, Starca L. Dehydroepiandrosterone – is the fontain of the youth drying out? Physiol Res 2003; 52: 397–407.
51. Seeman TE, Robbins RJ. Aging and hypothalamic-pituitary-adrenal response to challenge in humans. Endocrine Reviews 1994; 15: 233–60.
52. Spiegelman BM, Flier JS. Adipogenesis and obesity: rounding out the big picture. Cell 1996; 87: 377–89.
53. York D. Lessons from animal models of obesity. Endocr Metabol Clin N Am 1996; 25: 781–800.
54. Kirchengast S, Gruber D, Sator M, Huber J. Postmenopausal weight status, body composition and body fat distribution in relation to parameters of menstrual and reproductive history. Maturitas 1999; 33: 117–26.
55. The DECODE study group. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 2004; 164: 1066–76.
56. Miller AM, Wilbur J, Chandler PJ, Sorokin O. Cardiovascular disease risk factors and menopausal status in midlife women from the former Soviet Union. Women Health 2003; 38: 19–36.
57. Tremollieres FA, Pouilles JM, Ribot CA. Relative influence of age and menopause on total and regional body composition changes in postmenopausal women. Am J Obstet Gynecol 1996; 175 (6): 1594–600.
58. Rosano GM, Patrizi R, Leonardo F et al. Effect of estrogen replacement therapy on heart rate variability and heart rate in healthy postmenopausal women. Am J Cardiol 1997; 80 (6): 815–7.
59. Kaplan NM. The deadly quartet: upper-body obesity, glucose intolerance, hypertriglyceridemia and hypertension. Arch Intern Med 1989; 149: 1514–20.
60. Athyros VG, Ganotakis ES, Elisaf M, Mikhailidis DP. The prevalence of the metabolic syndrome using the National Cholesterol Education Program and International Diabetes Federation definitions. Curr Med Res Opin 2005; 21: 1157–9.
61. Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care 2005; 28: 2745–9.
62. Зимин Ю.В. Происхождение, диагностическая концепция и клиническое значение синдрома инсулинорезистентности или метаболического синдрома Х. Кардиология. 1998; 6: 71–81. / Zimin Iu.V. Proiskhozhdenie, diagnosticheskaia kontseptsiia i klinicheskoe znachenie sindroma insulinorezistentnosti ili metabolicheskogo sindroma Х. Kardiologiia. 1998; 6: 71–81. [in Russian]
63. Williams B. Insulin resistance: the shape of things to come. Lancet 1994; 344: 521–4.
64. Sowers JR, Standley PR, Ram JL et al. Hyperinsulinemia, insulin resistance and hyperglycemia: contributing factors in pathogenesis of hypertension and atherosclerosis. Am J Hypertens 1993; 6: S260–70.
65. Hotta K, Funahashi T, Bodkin NL et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 2001; 50: 1126–33.
66. Di Carlo C, Tommaselli GA, Nappi C. Effects of sex steroid hormones and menopause on serum leptin concentrations. Gynecol Endocrinol 2002; 16 (6): 479–91.
67. Ярных Е.В., Устинова С.Е., Масенко В.П. Особенности нейроэндокринной регуляции у женщин с эссенциальной гипертонией в климактерическом периоде. Артериальная гипертензия: патогенез, патогенетическая терапия, поражение органов. М., 1997; с. 85. / Iarnykh E.V., Ustinova S.E., Masenko V.P. Osobennosti neiroendokrinnoi reguliatsii u zhenshchin s essentsial'noi gipertoniei v klimaktericheskom periode. Arterial'naia gipertenziia: patogenez, patogeneticheskaia terapiia, porazhenie organov. M., 1997; s. 85. [in Russian]
68. Lindheim SR, Legro RS, Bernstein L et al. Behavioral stress responses in premenopausal and postmenopausal women and effect of estrogen. Am J Obstet Gynecol 1992; 167: 1831–6.
69. Sabogal JC, Munoz L. Leptin in obstetrics and gynecology: a review. Obstet Gynecol Surv 2001; 56 (4): 225–30.
70. Luukkaa V, Pesonen U, Huhtaniemi I et al. Inverse Correlation between Serum Testosteron and Leptin in Men. J Clin Endocrinol Metab 1998; 83: 3243–6.
71. Ballermann BJ. A role for leptin in glomerulosclerosis? Kidney Int 1999; 56: 1154–5.
72. Sharma K, Considine RV. The Ob protein (leptin) and the kidney. Kidney Int 1998; 53: 1483–7.
73. Wolf G, Chen Sh, Han DCh et al. Leptin and Renal Disease. Am J Kidney Dis 2002; 39 (1): 1–11.
74. Haynes WG, Morgan DA, Walsh SA et al. Receptor mediated regional sympathetic nerve activation by leptin. J Clin Invest 1997; 100: 270–8.
75. Haynes WG, Sivitz WI, Morgan DA et al. Sympathetic and cardiorenal actions of leptin. Hypertension 1997; 30: 619–23.
76. Narkiewicz K, Somers VK, Mos L et al. An independent relationship between plasma leptin and heart rate in untreated patients with essential hypertension. J Hypertension 1999; 17: 245–9.
77. Eikelis N, Schlaich M, Aggarwal A et al. Interactions between leptin and the human sympathetic nervous system. Hypertension 2003; 41: 1072–9.
78. Подзолков В.И., Булатов В.А. Ренин-ангиотензин-альдостероновая система как краеугольный камень сердечно-сосудистого и почечного континуума. Органопротективные свойства антагонистов рецепторов к ангиотензину II. Атмосфера. Кардиология. 2005; 3: 20–5. / Podzolkov V.I., Bulatov V.A. Renin-angiotenzin-al'dosteronovaia sistema kak kraeugol'nyi kamen' serdechno-sosudistogo i pochechnogo kontinuuma. Organoprotektivnye svoistva antagonistov retseptorov k angiotenzinu II. Atmosfera. Kardiologiia. 2005; 3: 20–5. [in Russisan]
79. Подзолков В.И., Булатов В.А. Миокард. Нефрон. Взгляд через призму эволюции артериальной гипертензии. Рус. мед. журн. 2008; 16 (11): 1517–23. / Podzolkov V.I., Bulatov V.A. Miokard. Nefron. Vzgliad cherez prizmu evoliutsii arterial'noi gipertenzii. Rus. med. zhurn. 2008; 16 (11): 1517–23. [in Russian]
80. Silverstein RL, Fenves AZ, Ram CV. ARBs and target organ protection. Exploring benefits beyond their antihypertensive effects. Postgrad Med 2004; 116: 31–41.
81. Wagenaar LJ, Voors AA, Buikema H, Van Gilst WH. Angiotensin receptors in the cardiovascular system. Can J Cardiol 2002; 18: 1331–9.
82. Schiffrin EL. Vascular and cardiac benefits of angiotensin receptor blockers. Am J Med 2002; 113: 409–18.
83. Stanton A. Therapeutic potential of renin inhibitors in the management of cardiovascular disorders. Am J Cardiovasc Drugs 2003; 3: 389–94.
84. Моисеева О.М., Лясникова Е.А., Семенова Е.Г. и др. Трансформирующий фактор-b и маркеры активации лейкоцитов при гипертонической болезни. Артериальная гипертензия. 2003; 9 (1): 14–6. / Moiseeva O.M., Liasnikova E.A., Semenova E.G. i dr. Transformiruiushchii faktor-b i markery aktivatsii leikotsitov pri gipertonicheskoi bolezni. Arterial'naia gipertenziia. 2003; 9 (1): 14–6. [in Russian]
85. Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int 2006; 69: 213–7.
86. Gill RK, Turner RT, Wronski TJ, Bell NH. Orchiectomy markedly reduces the concentration of the three isoforms of transforming growth factor beta in rat bone, and reduction is prevented by testosterone. Endocrinology 1998; 139: 546–50.
87. Gibbons GH, Pratt RE, Dzau VJ. Vascular smooth muscle cell hypertrophy vs hyperplasia: autocrine transforming growth factor beta 1 expression determines growth response to angiotensin II. J Clin Invest 1992; 90: 456–61.
88. Folkow B. Physiological aspect of primary hypertension. Physiol Reu 1982.
89. Quehenberger P, Exner M, Sunder-Plassmann R et al. Leptin induces endothelin-1 in endothelial cells in vitro. Circul Res 2002; 90: 711–8.
90. Montenson LH, Pawlowski CM, Kanady NL, Fink GD. Chronic hypertension produced by infusion of endothelin in rat. Hypertension 1990; 15: 729–33.
91. Wilkins FC, Alberola A, Mizelle HL et al. Systemic hemodynamics and renal function during long-term pathophysiological increases in circulating endothelin. Am J Physiol 1995; 268: 375–81.
92. Duerrschmidt N, Wippich N, Goettsch W et al. Endothelin-1 induces NAD(P)H oxidase in human endothelial cells. Biochem Biophys Res Comm 2000; 269: 713–7.
93. Komatsumoto S, Nara M. Changes in the level of endothelin-1 with aging. Nippon Ronen Igakkai Zasshi 1995; 32: 664–9.
94. Lacy F, Kailasam MT, O’′Connor DT et al. Plasma hydrogen peroxide production in human essential hypertension: role of heredity, gender, and ethnicity. Hypertension 2000; 36: 878–84.
95. Mollnau H, Wendt M, Szocs K et al. Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ Res 2002; 90: E58–E65.
96. Klug D, Robert V, Swynghedauw B et al. Role of mechanical and hormonal factors in cardiac remodeling and biologic limits of myocardial adaptation. Am J Cardiol 1993; 71: 46A–54A.
97. James GD, Sealey JE, Muller F et al. Renin Relationship to Sex, Race and Age in Normotensive Population. J Hypertension 1986; 4 (Suppl. 5): S387–9.
98. Fortepiani LA, Zhang H, Racusen L et al. Characterization of an animal model of menopausal hypertension in SHR. Hypertension 2003; 41: 460–3.
99. Reckelhoff JF. Gender differences in the regulation of blood pressure. Hypertension 2001; 37 (5): 1199–208.
100. De Nuccio I, Salvati G, Genovesi G et al. Physiopathology of the renin-angiotensin system in the ovary. Minerva Endocrinol 1999; 24: 77–81.
101. Anttila L, Penttila AT, Matinlauri I et al. Serum total renin levels after ovarian electrocautery in women with polycystic ovary syndrome. Gynecol Endocrinol 1998; 12: 327–31.
102. Erman A, Chen-Gal B, Van Dijk DJ et al. Ovarian angiotensin − converting enzyme activity in humans: relationship to estradiol, age, and uterine pathology. J Endocrinol Metab 1996; 81: 1104–7.
103. Маслова Н.П., Баранова Е.И. Гипертоническая болезнь у женщин. СПб.: Издательский дом СПбГМУ, 2000. / Maslova N.P., Baranova E.I. Gipertonicheskaia bolezn' u zhenshchin. SPb.: Izda­tel'skii dom SPbGMU, 2000. [in Russian]
104. Шхвацабая И.К., Устинова С.Е., Учитель И.А. и др. Низкорениновая форма гипертонической болезни: особенности функциональных соотношений прессорной системы ренин-альдостерон. Кардиология. 1983; 23 (4): 5–10. / Shkhvatsabaia I.K., Ustinova S.E., Uchitel' I.A. i dr. Nizkoreninovaia forma gipertonicheskoi bolezni: osobennosti funktsional'nykh sootnoshenii pressornoi sistemy renin-al'dosteron. Kardiologiia. 1983; 23 (4): 5–10. [in Russian]
105. Karpanou EA, Vyssoulis GP, Georgoudi DG et al. Ambulatory blood pressure changes in the menstrual cycle of hypertensive women. Am J Hypertension 1993; 6: 654–9.
106. Schunkert H, Danser AH, Hense HW et al. Effects of oestrogen replacement therapy on the renin-angiotensin system in postmenopausal women. Circulation 1997; 95 (1): 39–45.
107. Stanosz S, Kuligowski D. Excretion of free catecholomines in urine and water electrolyte balance in women with hypertension in the period before and after menopause. Gynecol Polska 1992; 63 (3): 300–3.
108. Villecco AS, De Aloysio D, Radi D et al. Plasma catecholamines in pre- and in postmenopausal women with mild to moderate essential hypertension. J Hum Hypertens 1997; 11 (3): 157–62.
109. Esler M, Rumantir M, Wiesner G et al. Sympathetic nervous system and insulin resistance: From obesity to diabetes. Am J Hypertension 2001; 14: 304S–309S.
110. Callister R, Johnson DG, Seals DR. Age and gender influence muscle sympathetic nerve activity at rest in healthy humans. Hypertension 1993; 21: 498–503.
111. Grassi G, Seravalle G, Cattaneo BM et al. Sympathetic activation in obese normotensive subjects. Hypertension 1995; 25: 560–63.
112. Alvarez GE, Beske SD, Ballard TP et al. Sympathetic neural activation in visceral obesity. Circulation 2002; 106: 2533–6.
113. Troisi RJ, Weiss ST, Parker DR et al. Relation of obesity and diet to sympathetic nervous system activity. Hypertension 1999; 17: 669–77.
114. Tuck ML. Obesity, the sympathetic nervous system, and essential hypertension. Hypertension 1992; 19: 167–77.
115. Ильина Э.М. Генез вегетативно-сосудистых расстройств у больных с климактерическим синдромом. Автореф. дис. … канд. мед. наук. М., 1986. / Il'ina E.M. Genez vegetativno-sosudistykh rasstroistv u bol'nykh s klimaktericheskim sindromom. Avtoref. dis. … kand. med. nauk. M., 1986. [in Russian]
116. Ткаченко Н.М. Состояние вегетативной нервной системы при физиологическом течении климактерического периода и климактерическом синдроме. М., 1988; с. 65–157. / Tkachenko N.M. Sostoianie vegetativnoi nervnoi sistemy pri fiziologicheskom techenii klimaktericheskogo perioda i klimaktericheskom sindrome. M., 1988; s. 65–157. [in Russian]
117. Назаренко Н.В., Туева Р.С. Особенности артериальной гипертензии и обмен катехоламинов у больных патологическим климаксом. Сборник научных трудов. Пермский медицинский институт. 1983; 140: 43–5. / Nazarenko N.V., Tueva R.S. Osobennosti arterial'noi gipertenzii i obmen katekholaminov u bol'nykh patologicheskim klimaksom. Sbornik nauchnykh trudov. Permskii meditsinskii institut. 1983; 140: 43–5. [in Russian]
118. Sudhir K, Else MP, Jennings GL, Komesaroff PA. Estrogen supplementation decreases norepinephrine-induced vasoconstriction and total body norepinephrine spill over in perimenopausal women. Hypertension 1997; 30: 1538–43.
119. Mercuro G, Zoncu S, Pilia J et al. Effect of acute administration of transdermal estrogen on postmenopausal women with systemic hypertension. Am J Cardiol 1997; 80: 652–5.
120. Подзолков В.И., Можарова Л.Г., Хомицкая Ю.В. Применение моксонидина для коррекции артериальной гипертонии у женщин с климактерическим синдромом. Кардиоваск. терапия и профилактика. 2005; 4 (5): 83–8. / Podzolkov V.I., Mozharova L.G., Khomitskaia Iu.V. Primenenie moksonidina dlia korrektsii arterial'noi gipertonii u zhenshchin s klimaktericheskim sindromom. Kardiovask. terapiia i profilaktika. 2005; 4 (5): 83–8. [in Russian]
121. Dubey RK, Oparil S, Imthurn B, Jackson EK. Sex hormones and hypertension. Cardiovasc Res 2002; 53 (3): 688–708.
122. Подзолкова Н.М., Подзолков В.И., Никитина Т.И. и др. Роль биогенных аминов в развитии полиметаболических нарушений после гистерэктомии. Проблемы репродукции. 2013; 2: 43–8. / Podzolkova N.M., Podzolkov V.I., Nikitina T.I. i dr. Rol' biogennykh aminov v razvitii polimetabolicheskikh narushenii posle gisterektomii. Problemy reproduktsii. 2013; 2: 43–8. [in Russian]
123. Маколкин В.И., Абакумов С.А., Сапожникова А.А. Нейроциркуляторная дистония. Чебоксары, 1995. / Makolkin V.I., Abakumov S.A., Sapozhnikova A.A. Neirotsirkuliatornaia distoniia. Cheboksary, 1995. [in Russian]
124. Подзолков В.И. Начальная стадия гипертонической болезни (патогенетические механизмы и обоснование терапии). Автореф. дис. … д-р мед. наук. М., 1994. / Podzolkov V.I. Nachal'naia stadiia gipertonicheskoi bolezni (patogeneticheskie mekhanizmy i obosnovanie terapii). Avtoref. dis. … d-r med. nauk. M., 1994. [in Russian]
125. Евсиков Е.М. Гормональные, гемодинамические и водно-электролитные факторы и механизмы в развитии гипертонической болезни у женщин. Автореф. дис. … д-ра мед. наук. М., 1994. / Evsikov E.M. Gormonal'nye, gemodinamicheskie i vodno-elektrolitnye faktory i mekhanizmy v razvitii gipertonicheskoi bolezni u zhenshchin. Avtoref. dis. … d-r med. nauk. M., 1994. [in Russian]
126. Schwartz JC, Arrang JM, Garbarg M et al. Histaminergic transmission in the mammalian brain. Physiol Rev 1991; 71: 1–51.
127. Bealer SL. Central Neuronal Histamine Contributes to Cardiovascular Regulation. News in Physiological Sciences 1999; 14 (3): 100–5.
128. Grekin RJ, Hamlyn JM. Acetylcholin, g-aminobutyric acid, serotonin, adenosine, and endogenous ouabain. In: Hypertension primer. The essentials of high blood pressure. Ed. J.L.Izzo, H.R.Black. Am Heart Assoc 2003; p. 47–9.
129. Reid RL. Premenstrual syndrome. Curr Probl Obstet Gynecol Fertil 1985; 8: 1.
130. Berecek KH, Carey RM. Adrenergic and dopaminergic receptors and activation. In: Hypertension primer. The essentials of high blood pressure. Ed. J.L.Izzo, H.Black. Am Heart Assoc 2003; p. 47–9.
131. Carey RM, Drake CR. Dopamine selectively inhibits aldosterone responses to angiotensin II in humans. Hypertension 1986; 8: 399–406.
132. DeMaria JE; Livingstone JD. Freeman ME. Ovarian steroids influence the activity of neuroendocrine dopaminergic neurons. Brain Res 2000; 879 (1–2): 139–47.
133. Verty AN, McGregor IS, Mallet PE. The dopamine receptor antagonist SCH 23390 attenuates feeding induced by 9-tetrahydrocannabinol. Brain Res 2004; 1020: 188–95.

________________________________________________

1. Bystrova M.M., Britov A.N. Arterial'naia gipertoniia u zhenshchin v postmenopauze. Kardiologiia. 1999; 5: 72–80. [in Russian]
2. Oganov R.G., Maslennikova G.Ia. Gendernye razlichiia kardiovaskuliarnoi patologii. Kardiovask. terapiia i profilaktika. 2012; 11 (4): 101–4. [in Russian]
3. Lloyd-Jones DM, Evans JC, Levy D. Hypertension in adults across the age spectrum: current outcomes and control in the community. JAMA 2005; 294: 466–72.
4. Mosca L, Hammond G, Mochari-Greenberger H et al. Fifteen-Year Trends in Awareness of Heart Disease in Women Results of a 2012 American Heart Association National Survey. Circulation published online February 19, 2013; available at http://circ.ahajournals.org/content/early/2013/02/19/CIR.0b013e318287cf2f
5. Taddei S. Blood pressure through aging and menopause. Climacteric 2009; 12 (Suppl. 1): 36–40.
6. Thom T, Haase N, Rosamond W et al. Heart disease and strokestatistics – 2006 update: a report from the American heart association statistics committee and stroke statistics subcommittee. Circulation 2006; 113: e85–151.
7. Mosca L, Appel LJ, Benjamin EJ et al. Evidence-based guidelines forcardiovascular disease prevention in women. Circulation 2004; 109: 672–93.
8. Beliakov N.A., Seidova G.B., Chubrieva N.V., Glukhov N.V. Metabolicheskii sindrom u zhenshchin. Spb.: Izdatel'skii dom SPbMAPO, 2005. [in Russian]
9. Bittner V. Women and coronary heart disease risk factors. J Cardiovasc Risk 2002; 9 (6): 315–22.
10. Kannel WB. The Framingham Study: historical insight on the impact of cardiovascular risk factors in men versus women. J Gend Specif Med 2002; 5 (2): 27–7.
11. Gangar KF, Vyas S, Whitehead M et al. Pulsatility index in internal carotid artery in relation to transdermal oestradiol and time since menopause. Lancet 1991; 338: 939–42.
12. Majmudar NG, Robinson SC, Ford GA. Effect of the Menopause, Gender and Hormone Replacement Therapy on Vascular Nitric Oxide Activity. J Clin Endocrinol Metab 2000; 85 (4): 1577–83.
13. Collins P, Rosano GMC, Jiang C et al. Cardiovascular protection by oestrogen – a calcium antagonist effect? Lancet 1993; 341: 1264–5.
14. Lieberman EH, Cerhard MD, Uehata A et al. Estrogens improves endothelium-dependent, flow-mediated vasodilatation in postmenopausal women. Ann Intern Med 1994: 121: 936–42.
15. Wogensen L. Transforming growth factor beta1-induced glomerulopathy is prevented by 17beta-estradiol supplementation. Virchows Arch 2004; 444: 561–6.
16. Birch Nielsen C, Krag S, Osterby R et al. Transforming growth factor beta1-induced glomerulopathy is prevented by 17beta-estradiol supplementation. Virchows Arch 2004; 444: 561–6.
17. Simoncini T, Genazzani AR. Non-genomic actions of sex steroid hormones. Eur J Endocrinol 2003; 148: 281–92.
18. Neugarten J, Acharya A, Lei J, Silbiger S. Selective estrogen receptor modulators suppress mesangial cell collagen synthesis. Am J Physiol Renal Physiol 2000; 279: F309–18.
19. Fisman EZ, Tenenbaum A, Pines A. Systemic hypertension in postmenopausal women: a clinical approach. Curr Hypertens Rep 2002; 4 (6): 464–70.
20. Schunkert H, Danser AH, Hense HW et al. Effects of oestrogen replacement therapy on the renin-angiotensin system in postmenopausal women. Circulation 1997; 95 (1): 39–45.
21. Wood MJ, Cox Jl. HRT to prevent cardiovascular disease. What studies show, how to advise patients. Postgrad med 2000; 108 (3): 59–72.
22. Henriksson P, Stege R, Green K. Profound decrease of in vivo formation of thromboxane during oestrogen therapy. Eur J Clin Invest 1996; 26 (12): 1186–8.
23. Tostes RC, Nigro D, Fortes ZB et al. Effects of estrogen on the vascular system. Braz J Med Biol Res 2003; 36 (9): 1143–58.
24. Kalish MK, Barret-Connor E, Laughlin GA, Gulansky BI. Association of endogenous sex hormones and insulin resistance among postmenopausal women: results from the postmenopausal estrogen/progestin intervention trial. J Clin Endocrinol Metab 2003; 88 (4): 1646–52.
25. Carr MC. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab 2003; 88 (6): 2404–11.
26. Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010; 17 (2): 242–55.
27. Barbagallo M, Shan J, Pang PK, Resnick LM. Vascular effects of progesterone: role of intracellular calcium metabolism. Am J Hypertens 1995; 8 (4): 66A.
28. Landau RL, Poulos JT. The metabolic influence of progestins. Adv Metab Disord 1971; 5: 119–47.
29. Laragh JH. Renin-angiotensin-aldosteron system for blood pressure and elecrolyte homeostasis and its involvement in hypertension, in congestive heart failure and in associated cardiovascular damage (myocardial infarction and stroke). J Hum Hypertens 1995; 9 (6): 385–90.
30. Sealey JE, Itskovitz-Eldor J, Rubattu S et al. Estradiol and progesterone related increases in renin-aldosteron system during ovarian stimulation and early pregnancy. J Clin Endocrinol Metab 1994; 79 (1): 258–64.
31. Staessen JA, Bieniaszewski L, Brosens I, Fagard R. The epidemiology of menopause and associated cardiovascular disease. In: Hypertension after menopause. M.Stimpel, A.Zanchetti (ed.). de Gruyter. Berlin–New-York, 1997; p. 21–9.
32. Iarnykh E.V. Arterial'naia gipertoniia u zhenshchin v klimaktericheskom periode: klinicheskie osobennosti, sostoianie dofaminergicheskoi aktivnosti i insulinorezistentnosti. Obosnovanie gipotenzivnoi terapii: Avtoref. dis. … kand. med. nauk. M., 2000. [in Russian]
33. Malichenko S.B., Ovchinnikova S.G. Postmenopauzal'nyi metabolicheskii sindrom: novye vozmozhnosti terapii. Farmateka. 2004; 6 (84): 73–8. [in Russian]
34. Jiroutek MR, Chen MH, Johnston CC, Longcope C. Changes in Reproductive Hormones and Sex Hormone-Binding Globulin in a Group of Postmenopausal Women Measured Over 10 Years. Menopause 1998; 5: 90–4.
35. Fortepiani LA, Zhang H, Racusen L et al. Characterization of an animal model of postmenopausal hypertension in SHR. Hypertension 2003; 41: 460–3.
36. Laughlin GA, Barrett-Connor E, Kritz-Silverstein D, Von Muhlen D. Hysterectomy, oophorectomy, and endogenous sex hormone levels in older women: the Rancho Bernardo study. J Clin Endocrinol Metab 2000; 85: 645–51.
37. Hartmann BW, Kirchengast S, Albrecht A et al. Androgen Serum Levels in Women With Premature Ovarian Failure Compared to Fertile and Menopausal Controls. Gynecol Obstet Invest 1997; 44: 127–31.
38. Overlie I, Moen MH, Morkfid L et al. The Endocrine Transition Around Menopause – a Five Years Prospective Study with Profiles of Gonadotropins, Estrogens, Androgens and SHBG Among Healthy Women. Acta Obstet Gynecol Scand 1999; 78: 642–7.
39. Janssen I, Powell LH, Kazlauskaite R, Dugan SA. Testosterone and Visceral Fat in Midlife Women: The Study of Women's Health Across the Nation (SWAN) Fat Patterning Study. Obesity 2010; 18: 604–10.
40. Janssen I, Powell LH, Crawford S et al. Menopause and the Metabolic Syndrome. The Study of Women’s Health Across the Nation. Arch Intern Med 2008; 168 (14): 1568–75.
41. Chen YF, Naftilan AJ, Oparil S. Androgen-Dependent Angiotensinogen and Renin Messenger RNA Expression in Hypertensive Rats. Hypertension 1992; 9: 456–63.
42. Ellison KE, Ingelfinger JR, Pivor M, Dzau VJ. Androgen Regulation of Rat Renal Angiotensinogen Messenger RNA Expression. J Clin Invest 1989; 83: 1941–5.
43. Katz FH, Roper EF. Testosterone effect on renin system in rats. Proc Soc Exp Biol Medical 1977; 155: 330–3.
44. Van Kesteren PJ, Kooistra T, Lansink M et al. The effects of sex steroids on plasma levels of marker proteins of endothelial cell functioning. Thromb Haemost 1998; 79: 1029−33.
45. Stener-Victorin E, Jedel E, Janson PO, Sverrisdottir YB. Low-frequency Electro-Acupuncture and Physical Exercise Decrease High Muscle Sympathetic Nerve Activity in Polycystic Ovary Syndrome. Am J Physiol Regul Integr Comp Physiol 2009; 3.
46. Orentreich N, Brind JL, Vogelman JN et al. Long-term longitudinal measurements of plasma dehydroepiandrosterone sulfate in normal men. J Clin Endocrinol Metab 1992; 75: 1002–4.
47. Sulcova J, Hill M, Hampl R, Starka L. Age and sex related differences in serum levels of unconjugated dehydroepiandrosterone and its sulphate in normal subjects. J Endocrinol 1997; 154: 57–62.
48. Schriock ED, Buffington CK, Hubert GD et al. Divergent correlations of circulating dehydroepiandrosterone sulfate and testosterone with insulin levels and insulin receptor binding. J Clin Endocrinol Metab 1988; 66: 1329–31.
49. Suzuki M, Kanazawa A, Hasegawa M et al. A close association between insulin resistance and dehydroepiandrosterone sulfate in subjects with essential hypertension. Endocr J 1999; 46: 521–8.
50. Celec P, Starca L. Dehydroepiandrosterone – is the fontain of the youth drying out? Physiol Res 2003; 52: 397–407.
51. Seeman TE, Robbins RJ. Aging and hypothalamic-pituitary-adrenal response to challenge in humans. Endocrine Reviews 1994; 15: 233–60.
52. Spiegelman BM, Flier JS. Adipogenesis and obesity: rounding out the big picture. Cell 1996; 87: 377–89.
53. York D. Lessons from animal models of obesity. Endocr Metabol Clin N Am 1996; 25: 781–800.
54. Kirchengast S, Gruber D, Sator M, Huber J. Postmenopausal weight status, body composition and body fat distribution in relation to parameters of menstrual and reproductive history. Maturitas 1999; 33: 117–26.
55. The DECODE study group. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 2004; 164: 1066–76.
56. Miller AM, Wilbur J, Chandler PJ, Sorokin O. Cardiovascular disease risk factors and menopausal status in midlife women from the former Soviet Union. Women Health 2003; 38: 19–36.
57. Tremollieres FA, Pouilles JM, Ribot CA. Relative influence of age and menopause on total and regional body composition changes in postmenopausal women. Am J Obstet Gynecol 1996; 175 (6): 1594–600.
58. Rosano GM, Patrizi R, Leonardo F et al. Effect of estrogen replacement therapy on heart rate variability and heart rate in healthy postmenopausal women. Am J Cardiol 1997; 80 (6): 815–7.
59. Kaplan NM. The deadly quartet: upper-body obesity, glucose intolerance, hypertriglyceridemia and hypertension. Arch Intern Med 1989; 149: 1514–20.
60. Athyros VG, Ganotakis ES, Elisaf M, Mikhailidis DP. The prevalence of the metabolic syndrome using the National Cholesterol Education Program and International Diabetes Federation definitions. Curr Med Res Opin 2005; 21: 1157–9.
61. Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care 2005; 28: 2745–9.
62. Zimin Iu.V. Proiskhozhdenie, diagnosticheskaia kontseptsiia i klinicheskoe znachenie sindroma insulinorezistentnosti ili metabolicheskogo sindroma Х. Kardiologiia. 1998; 6: 71–81. [in Russian]
63. Williams B. Insulin resistance: the shape of things to come. Lancet 1994; 344: 521–4.
64. Sowers JR, Standley PR, Ram JL et al. Hyperinsulinemia, insulin resistance and hyperglycemia: contributing factors in pathogenesis of hypertension and atherosclerosis. Am J Hypertens 1993; 6: S260–70.
65. Hotta K, Funahashi T, Bodkin NL et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 2001; 50: 1126–33.
66. Di Carlo C, Tommaselli GA, Nappi C. Effects of sex steroid hormones and menopause on serum leptin concentrations. Gynecol Endocrinol 2002; 16 (6): 479–91.
67. Iarnykh E.V., Ustinova S.E., Masenko V.P. Osobennosti neiroendokrinnoi reguliatsii u zhenshchin s essentsial'noi gipertoniei v klimaktericheskom periode. Arterial'naia gipertenziia: patogenez, patogeneticheskaia terapiia, porazhenie organov. M., 1997; s. 85. [in Russian]
68. Lindheim SR, Legro RS, Bernstein L et al. Behavioral stress responses in premenopausal and postmenopausal women and effect of estrogen. Am J Obstet Gynecol 1992; 167: 1831–6.
69. Sabogal JC, Munoz L. Leptin in obstetrics and gynecology: a review. Obstet Gynecol Surv 2001; 56 (4): 225–30.
70. Luukkaa V, Pesonen U, Huhtaniemi I et al. Inverse Correlation between Serum Testosteron and Leptin in Men. J Clin Endocrinol Metab 1998; 83: 3243–6.
71. Ballermann BJ. A role for leptin in glomerulosclerosis? Kidney Int 1999; 56: 1154–5.
72. Sharma K, Considine RV. The Ob protein (leptin) and the kidney. Kidney Int 1998; 53: 1483–7.
73. Wolf G, Chen Sh, Han DCh et al. Leptin and Renal Disease. Am J Kidney Dis 2002; 39 (1): 1–11.
74. Haynes WG, Morgan DA, Walsh SA et al. Receptor mediated regional sympathetic nerve activation by leptin. J Clin Invest 1997; 100: 270–8.
75. Haynes WG, Sivitz WI, Morgan DA et al. Sympathetic and cardiorenal actions of leptin. Hypertension 1997; 30: 619–23.
76. Narkiewicz K, Somers VK, Mos L et al. An independent relationship between plasma leptin and heart rate in untreated patients with essential hypertension. J Hypertension 1999; 17: 245–9.
77. Eikelis N, Schlaich M, Aggarwal A et al. Interactions between leptin and the human sympathetic nervous system. Hypertension 2003; 41: 1072–9.
78. Podzolkov V.I., Bulatov V.A. Renin-angiotenzin-al'dosteronovaia sistema kak kraeugol'nyi kamen' serdechno-sosudistogo i pochechnogo kontinuuma. Organoprotektivnye svoistva antagonistov retseptorov k angiotenzinu II. Atmosfera. Kardiologiia. 2005; 3: 20–5. [in Russisan]
79. Podzolkov V.I., Bulatov V.A. Miokard. Nefron. Vzgliad cherez prizmu evoliutsii arterial'noi gipertenzii. Rus. med. zhurn. 2008; 16 (11): 1517–23. [in Russian]
80. Silverstein RL, Fenves AZ, Ram CV. ARBs and target organ protection. Exploring benefits beyond their antihypertensive effects. Postgrad Med 2004; 116: 31–41.
81. Wagenaar LJ, Voors AA, Buikema H, Van Gilst WH. Angiotensin receptors in the cardiovascular system. Can J Cardiol 2002; 18: 1331–9.
82. Schiffrin EL. Vascular and cardiac benefits of angiotensin receptor blockers. Am J Med 2002; 113: 409–18.
83. Stanton A. Therapeutic potential of renin inhibitors in the management of cardiovascular disorders. Am J Cardiovasc Drugs 2003; 3: 389–94.
84. Moiseeva O.M., Liasnikova E.A., Semenova E.G. i dr. Transformiruiushchii faktor-b i markery aktivatsii leikotsitov pri gipertonicheskoi bolezni. Arterial'naia gipertenziia. 2003; 9 (1): 14–6. [in Russian]
85. Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int 2006; 69: 213–7.
86. Gill RK, Turner RT, Wronski TJ, Bell NH. Orchiectomy markedly reduces the concentration of the three isoforms of transforming growth factor beta in rat bone, and reduction is prevented by testosterone. Endocrinology 1998; 139: 546–50.
87. Gibbons GH, Pratt RE, Dzau VJ. Vascular smooth muscle cell hypertrophy vs hyperplasia: autocrine transforming growth factor beta 1 expression determines growth response to angiotensin II. J Clin Invest 1992; 90: 456–61.
88. Folkow B. Physiological aspect of primary hypertension. Physiol Reu 1982.
89. Quehenberger P, Exner M, Sunder-Plassmann R et al. Leptin induces endothelin-1 in endothelial cells in vitro. Circul Res 2002; 90: 711–8.
90. Montenson LH, Pawlowski CM, Kanady NL, Fink GD. Chronic hypertension produced by infusion of endothelin in rat. Hypertension 1990; 15: 729–33.
91. Wilkins FC, Alberola A, Mizelle HL et al. Systemic hemodynamics and renal function during long-term pathophysiological increases in circulating endothelin. Am J Physiol 1995; 268: 375–81.
92. Duerrschmidt N, Wippich N, Goettsch W et al. Endothelin-1 induces NAD(P)H oxidase in human endothelial cells. Biochem Biophys Res Comm 2000; 269: 713–7.
93. Komatsumoto S, Nara M. Changes in the level of endothelin-1 with aging. Nippon Ronen Igakkai Zasshi 1995; 32: 664–9.
94. Lacy F, Kailasam MT, O’′Connor DT et al. Plasma hydrogen peroxide production in human essential hypertension: role of heredity, gender, and ethnicity. Hypertension 2000; 36: 878–84.
95. Mollnau H, Wendt M, Szocs K et al. Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ Res 2002; 90: E58–E65.
96. Klug D, Robert V, Swynghedauw B et al. Role of mechanical and hormonal factors in cardiac remodeling and biologic limits of myocardial adaptation. Am J Cardiol 1993; 71: 46A–54A.
97. James GD, Sealey JE, Muller F et al. Renin Relationship to Sex, Race and Age in Normotensive Population. J Hypertension 1986; 4 (Suppl. 5): S387–9.
98. Fortepiani LA, Zhang H, Racusen L et al. Characterization of an animal model of menopausal hypertension in SHR. Hypertension 2003; 41: 460–3.
99. Reckelhoff JF. Gender differences in the regulation of blood pressure. Hypertension 2001; 37 (5): 1199–208.
100. De Nuccio I, Salvati G, Genovesi G et al. Physiopathology of the renin-angiotensin system in the ovary. Minerva Endocrinol 1999; 24: 77–81.
101. Anttila L, Penttila AT, Matinlauri I et al. Serum total renin levels after ovarian electrocautery in women with polycystic ovary syndrome. Gynecol Endocrinol 1998; 12: 327–31.
102. Erman A, Chen-Gal B, Van Dijk DJ et al. Ovarian angiotensin − converting enzyme activity in humans: relationship to estradiol, age, and uterine pathology. J Endocrinol Metab 1996; 81: 1104–7.
103. Maslova N.P., Baranova E.I. Gipertonicheskaia bolezn' u zhenshchin. SPb.: Izda­tel'skii dom SPbGMU, 2000. [in Russian]
104. Shkhvatsabaia I.K., Ustinova S.E., Uchitel' I.A. i dr. Nizkoreninovaia forma gipertonicheskoi bolezni: osobennosti funktsional'nykh sootnoshenii pressornoi sistemy renin-al'dosteron. Kardiologiia. 1983; 23 (4): 5–10. [in Russian]
105. Karpanou EA, Vyssoulis GP, Georgoudi DG et al. Ambulatory blood pressure changes in the menstrual cycle of hypertensive women. Am J Hypertension 1993; 6: 654–9.
106. Schunkert H, Danser AH, Hense HW et al. Effects of oestrogen replacement therapy on the renin-angiotensin system in postmenopausal women. Circulation 1997; 95 (1): 39–45.
107. Stanosz S, Kuligowski D. Excretion of free catecholomines in urine and water electrolyte balance in women with hypertension in the period before and after menopause. Gynecol Polska 1992; 63 (3): 300–3.
108. Villecco AS, De Aloysio D, Radi D et al. Plasma catecholamines in pre- and in postmenopausal women with mild to moderate essential hypertension. J Hum Hypertens 1997; 11 (3): 157–62.
109. Esler M, Rumantir M, Wiesner G et al. Sympathetic nervous system and insulin resistance: From obesity to diabetes. Am J Hypertension 2001; 14: 304S–309S.
110. Callister R, Johnson DG, Seals DR. Age and gender influence muscle sympathetic nerve activity at rest in healthy humans. Hypertension 1993; 21: 498–503.
111. Grassi G, Seravalle G, Cattaneo BM et al. Sympathetic activation in obese normotensive subjects. Hypertension 1995; 25: 560–63.
112. Alvarez GE, Beske SD, Ballard TP et al. Sympathetic neural activation in visceral obesity. Circulation 2002; 106: 2533–6.
113. Troisi RJ, Weiss ST, Parker DR et al. Relation of obesity and diet to sympathetic nervous system activity. Hypertension 1999; 17: 669–77.
114. Tuck ML. Obesity, the sympathetic nervous system, and essential hypertension. Hypertension 1992; 19: 167–77.
115. Il'ina E.M. Genez vegetativno-sosudistykh rasstroistv u bol'nykh s klimaktericheskim sindromom. Avtoref. dis. … kand. med. nauk. M., 1986. [in Russian]
116. Tkachenko N.M. Sostoianie vegetativnoi nervnoi sistemy pri fiziologicheskom techenii klimaktericheskogo perioda i klimaktericheskom sindrome. M., 1988; s. 65–157. [in Russian]
117. Nazarenko N.V., Tueva R.S. Osobennosti arterial'noi gipertenzii i obmen katekholaminov u bol'nykh patologicheskim klimaksom. Sbornik nauchnykh trudov. Permskii meditsinskii institut. 1983; 140: 43–5. [in Russian]
118. Sudhir K, Else MP, Jennings GL, Komesaroff PA. Estrogen supplementation decreases norepinephrine-induced vasoconstriction and total body norepinephrine spill over in perimenopausal women. Hypertension 1997; 30: 1538–43.
119. Mercuro G, Zoncu S, Pilia J et al. Effect of acute administration of transdermal estrogen on postmenopausal women with systemic hypertension. Am J Cardiol 1997; 80: 652–5.
120. Podzolkov V.I., Mozharova L.G., Khomitskaia Iu.V. Primenenie moksonidina dlia korrektsii arterial'noi gipertonii u zhenshchin s klimaktericheskim sindromom. Kardiovask. terapiia i profilaktika. 2005; 4 (5): 83–8. [in Russian]
121. Dubey RK, Oparil S, Imthurn B, Jackson EK. Sex hormones and hypertension. Cardiovasc Res 2002; 53 (3): 688–708.
122. Podzolkova N.M., Podzolkov V.I., Nikitina T.I. i dr. Rol' biogennykh aminov v razvitii polimetabolicheskikh narushenii posle gisterektomii. Problemy reproduktsii. 2013; 2: 43–8. [in Russian]
123. Makolkin V.I., Abakumov S.A., Sapozhnikova A.A. Neirotsirkuliatornaia distoniia. Cheboksary, 1995. [in Russian]
124. Podzolkov V.I. Nachal'naia stadiia gipertonicheskoi bolezni (patogeneticheskie mekhanizmy i obosnovanie terapii). Avtoref. dis. … d-r med. nauk. M., 1994. [in Russian]
125. Evsikov E.M. Gormonal'nye, gemodinamicheskie i vodno-elektrolitnye faktory i mekhanizmy v razvitii gipertonicheskoi bolezni u zhenshchin. Avtoref. dis. … d-r med. nauk. M., 1994. [in Russian]
126. Schwartz JC, Arrang JM, Garbarg M et al. Histaminergic transmission in the mammalian brain. Physiol Rev 1991; 71: 1–51.
127. Bealer SL. Central Neuronal Histamine Contributes to Cardiovascular Regulation. News in Physiological Sciences 1999; 14 (3): 100–5.
128. Grekin RJ, Hamlyn JM. Acetylcholin, g-aminobutyric acid, serotonin, adenosine, and endogenous ouabain. In: Hypertension primer. The essentials of high blood pressure. Ed. J.L.Izzo, H.R.Black. Am Heart Assoc 2003; p. 47–9.
129. Reid RL. Premenstrual syndrome. Curr Probl Obstet Gynecol Fertil 1985; 8: 1.
130. Berecek KH, Carey RM. Adrenergic and dopaminergic receptors and activation. In: Hypertension primer. The essentials of high blood pressure. Ed. J.L.Izzo, H.Black. Am Heart Assoc 2003; p. 47–9.
131. Carey RM, Drake CR. Dopamine selectively inhibits aldosterone responses to angiotensin II in humans. Hypertension 1986; 8: 399–406.
132. DeMaria JE; Livingstone JD. Freeman ME. Ovarian steroids influence the activity of neuroendocrine dopaminergic neurons. Brain Res 2000; 879 (1–2): 139–47.
133. Verty AN, McGregor IS, Mallet PE. The dopamine receptor antagonist SCH 23390 attenuates feeding induced by 9-tetrahydrocannabinol. Brain Res 2004; 1020: 188–95.

В.И.Подзолков1, А.Е.Брагина*1, Ю.Н.Родионова1, Ю.А.Колода2

1 ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава России. 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 1;
2 ГБОУ ДПО Российская медицинская академия последипломного образования Минздрава России. 123995, Россия, Москва, ул. Баррикадная, д. 2/1
*anna.bragina@mail.ru

________________________________________________

V.I.Podzolkov1, A.E.Bragina*1, J.N.Rodionova1, J.A.Koloda2

1 I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation. 119991, Russian Federation, Moscow, ul. Trubetskaya d. 8, str. 1;
2 Russian Medical Academy of Post-diplom a Education of the Ministry of Health of the Russian Federation. 123995, Russian Federation, Moscow, ul. Barrikadnaya, d. 2/1
*anna.bragina@mail.ru